Managing bio-technical risks and future institutional health infrastructures.
γThe failures exposed by recent global health emergencies were primarily institutional, not scientific. Diagnostic capacity, supply-chain resilience, and inter-agency coordination all collapsed under strain — we evaluate preparedness architectures across jurisdictions and propose governance reforms that can survive the political cycle.
Universal health coverage requires financing models robust to demographic shifts, downturns, and rising treatment costs. We study how pooling mechanisms, benefit packages, and provider payment systems perform under fiscal pressure.
Gene editing, synthetic biology, and AI-driven drug discovery are converging faster than regulatory capacity. We focus on dual-use research oversight and international harmonisation of biosecurity standards.